There are 2949 resources available
1081MO - Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
Presenter: Anna Di Giacomo
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
891MO - Role of baseline PET SUVmax in predicting early progression in follicular lymphoma (FL): A single-center retrospective analysis
Presenter: Ayushi Chauhan
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
1082MO - 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone
Presenter: Caroline Robert
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1083MO - Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
Presenter: Cara Haymaker
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
529MO - Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer
Presenter: Mohamed Gouda
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
915MO - Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Richard Greil
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
531MO - VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy (IT) phase I clinical trials
Presenter: Alberto Hernando-Calvo
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
532MO - A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour
Presenter: Ying Cheng
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
533MO - Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
Presenter: Nicolas Girard
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
534MO - First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with advanced or metastatic solid tumours
Presenter: Noboru Yamamoto
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast